RIGEL PHARMACEUTICALS, INC. Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss
RIGEL PHARMACEUTICALS, INC. (RIGL) had Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss of $2.00 thousand as of 2013-12-31, per its 10-K filed 2015-03-03.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesContinuousUnrealizedLossPosition12MonthsOrLongerAccumulatedLoss · last filed 2015-03-03
- 2013-12-31: Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss $2.00K.
| Period end | Available-for-sale Securities, Continuous Unrealized Loss Position, 12 Months or Longer, Accumulated Loss |
|---|---|
| 2013-12-31 | $2.00K 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| ARDELYX, INC. (ARDX) | United States | $0.857B | -22.86 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 |